Developing a Framework for Scaling Preclinical Findings to Clinical Success in Cannabinoid Drug Development
Time: 11:00 am
day: Day Two
Details:
- Navigating regulatory pathways for cannabinoid medicines – insights from the development of Epidiolex and Sativex, including botanical drug guidance, fixed dose concentration, and the FDA 505(b)(2) pathway
- Streamlining approval and compliance for minor cannabinoids – strategies for aligning with regulatory guidelines to ensure safety and efficacy, focusing on cannabinoid combination studies (entourage vs non-tourage)
- Discussing updates on recent findings and results from ongoing clinical trials in cannabinoid drug development
